Vasopressin and oxytocin receptors in GtoPdb v.2023.1
Daniel G. Bichet(Hôpital du Sacré-Cœur de Montréal), Hans H. Zingg(McGill University), Mark A. Knepper(National Heart Lung and Blood Institute), Gerald Gimpl(Johannes Gutenberg University Mainz), Tadashi Kimura(Osaka University), Joseph G. Verbalis(Georgetown University), Melvyn S. Soloff(University of Toledo Medical Center), Gilles Guillon(Centre National de la Recherche Scientifique), Stephen J. Lolait(University of Bristol), Michel Bouvier(Institute for Research in Immunology and Cancer), Bice Chini(Neuroscience Institute), Anne‐Marie O’Carroll(University of Bristol), Claudine Serradeil‐Le Gal(Sanofi (Turkey)), Mark Wheatley(University of Nottingham), Maurice Manning(University of Toledo), Bernard Mouillac(Centre National de la Recherche Scientifique)
Cited by 2
Related Papers
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|Intensive Care Medicine|2014|1k
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|European Journal of Endocrinology|2014|823
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
|Journal of Clinical Investigation|2000|561
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555